HERV-K envelope glycoproteins harbor immunosuppressive activity and could inhibit the function of various immune cells (32), but it is unknown whether cancer-specific HERV-K-Env proteins are present in the circulating blood of patients, and whether circulating K-Env is associated with immune dysfunction. Here, ERVW-1 is linked to cancer.